Get started
Author

Stefania Oliva

Observed names: OLIVA, STEFANIA, S Oliva, S., Oliva
ORCID: 0000-0002-3084-180X
Observed ORCID: 0000-0002-3084-180X
OpenAlex ID: A5026044907
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
2015 · Antonio Palumbo, Hervé Avet-Loiseau, et al. · Journal of Clinical Oncology · 2,209
PDF
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
2020 · Michele Cavo, Francesca Gay, et al. · The Lancet Haematology · 381
PDF
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
2015 · Francesca Gay, Stefania Oliva, et al. · The Lancet Oncology · 314
PDF
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
2020 · Stefania Oliva, Mattia D'Agostino, et al. · Frontiers in Oncology · 291
PDF
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
2020 · Ajai Chari, Mehmet Kemal Samur, et al. · Blood · 187
PDF
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
2014 · Sara Bringhen, Maria Teresa Petrucci, et al. · Blood · 153
PDF
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
2017 · Francesca Gay, Monika Engelhardt, et al. · Haematologica · 124
PDF
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
2022 · Luca Bertamini, Stefania Oliva, et al. · Journal of Clinical Oncology · 94
PDF
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival
2014 · S Ferrero, M Ladetto, et al. · Leukemia · 85
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
2013 · Francesca Gay, Valeria Magarotto, et al. · Blood · 80
PDF
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing
2020 · Mattia D'Agostino, Gian Maria Zaccaria, et al. · Clinical Cancer Research · 64
PDF
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
2018 · Stefania Oliva, Rossella Troia, et al. · Frontiers in Immunology · 60
PDF
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
2020 · Niccolo Bolli, Elisa Genuardi, et al. · Frontiers in Oncology · 53
PDF
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
2021 · Stefania Oliva, Davine Hofste op Bruinink, et al. · Blood Cancer Journal · 49
PDF
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma
2017 · Mariateresa Fulciniti, Joaquin Martinez-Lopez, et al. · Blood · 46
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma
2016 · A Larocca, S Bringhen, et al. · Leukemia · 45
Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
2025 · Qian Shi, Bruno Paiva, et al. · Journal of Clinical Oncology · 44
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
2016 · F Gay, S Oliva, et al. · Leukemia · 44
PDF
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
2023 · Elena Zamagni, Stefania Oliva, et al. · EClinicalMedicine · 40
PDF
Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
2018 · Manuela Gambella, Paola Omedé, et al. · Cancer · 40
PDF
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
2023 · Mattia D’Agostino, Giuseppe Bertuglia, et al. · Blood · 39
PDF
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
2020 · Paolo Milani, Francesca Fazio, et al. · American Journal of Hematology · 36
PDF
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
2016 · Stefania Oliva, Manuela Gambella, et al. · Oncotarget · 36
PDF
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
2019 · Mattia D'Agostino, Luca Bertamini, et al. · Cancers · 35
PDF
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
2018 · Na Li, Michael A. Lopez, et al. · Clinical Cancer Research · 35
Works count: 67
Citation count: 4,867
H-index: 27
I10-index: 36
Year
Topic
Type